OBJECTIVES: Ecological, in vitro, and in vivo studies demonstrate a link between vitamin D and prostate tumor growth and aggressiveness. The goal of this study was to investigate whether plasma concentration of vitamin D is associated with survivorship and disease progression in men diagnosed with prostate cancer. MATERIALS AND METHODS: We conducted a population-based cohort study of 1476 prostate cancer patients to assess disease recurrence/progression and prostate cancer-specific mortality (PCSM) risks associated with serum levels of 25(OH) vitamin D [25(OH)D]. RESULTS: There were 325 recurrence/progression and 95 PCSM events during an average of 10.8 years of follow-up. Serum levels of 25(OH)D were not associated with risk of recurrence/progression or mortality. Clinically deficient vitamin D levels were associated with an increased risk of death from other causes. CONCLUSIONS: We did not find evidence that serum vitamin D levels measured after diagnosis affect prostate cancer prognosis. Lower levels of vitamin D were associated with risk of non-prostate cancer mortality.
OBJECTIVES: Ecological, in vitro, and in vivo studies demonstrate a link between vitamin D and prostate tumor growth and aggressiveness. The goal of this study was to investigate whether plasma concentration of vitamin D is associated with survivorship and disease progression in men diagnosed with prostate cancer. MATERIALS AND METHODS: We conducted a population-based cohort study of 1476 prostate cancerpatients to assess disease recurrence/progression and prostate cancer-specific mortality (PCSM) risks associated with serum levels of 25(OH) vitamin D [25(OH)D]. RESULTS: There were 325 recurrence/progression and 95 PCSM events during an average of 10.8 years of follow-up. Serum levels of 25(OH)D were not associated with risk of recurrence/progression or mortality. Clinically deficient vitamin D levels were associated with an increased risk of death from other causes. CONCLUSIONS: We did not find evidence that serum vitamin D levels measured after diagnosis affect prostate cancer prognosis. Lower levels of vitamin D were associated with risk of non-prostate cancer mortality.
Authors: Jonathan N Hofmann; Kai Yu; Ronald L Horst; Richard B Hayes; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Sarah K Holt; Erika M Kwon; Joseph S Koopmeiners; Daniel W Lin; Ziding Feng; Elaine A Ostrander; Ulrike Peters; Janet L Stanford Journal: Prostate Date: 2010-09-15 Impact factor: 4.104
Authors: Whitney K Hendrickson; Richard Flavin; Julie L Kasperzyk; Michelangelo Fiorentino; Fang Fang; Rosina Lis; Christopher Fiore; Kathryn L Penney; Jing Ma; Philip W Kantoff; Meir J Stampfer; Massimo Loda; Lorelei A Mucci; Edward Giovannucci Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Rebecca Gilbert; Richard M Martin; Rebecca Beynon; Ross Harris; Jelena Savovic; Luisa Zuccolo; Geertruida E Bekkering; William D Fraser; Jonathan A C Sterne; Chris Metcalfe Journal: Cancer Causes Control Date: 2011-01-04 Impact factor: 2.506
Authors: Fang Fang; Julie L Kasperzyk; Irene Shui; Whitney Hendrickson; Bruce W Hollis; Katja Fall; Jing Ma; J Michael Gaziano; Meir J Stampfer; Lorelei A Mucci; Edward Giovannucci Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: C J Paller; Y M Kanaan; D A Beyene; T J Naab; R L Copeland; H L Tsai; N F Kanarek; T S Hudson Journal: Prostate Date: 2015-06-05 Impact factor: 4.104
Authors: Irene M Shui; Alison M Mondul; Sara Lindström; Konstantinos K Tsilidis; Ruth C Travis; Travis Gerke; Demetrius Albanes; Lorelei A Mucci; Edward Giovannucci; Peter Kraft Journal: Cancer Date: 2015-03-02 Impact factor: 6.860